A microRNA circuit mediates transforming growth factor-Β1 autoregulation in renal glomerular mesangial cells

Kidney International

Volumn 80, Issue 4, 2011, Pages 358-368

  Kato, Mitsuo ^a   Arce, Laura ^a   Wang, Mei ^a   Putta, Sumanth ^a   Lanting, Linda ^a   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

cell signaling; diabetic nephropathy; fibrosis; gene expression; TGF

Indexed keywords

MICRORNA; MICRORNA 192; MICRORNA 200B; MICRORNA 200C; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BINDING TO IGHM ENHANCER 3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 1; ZEB1 PROTEIN; ZEB2 PROTEIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; COL4A1 GENE; COLLAGEN TYPE I ALPHA2 GENE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; E BOX ELEMENT; GENE; GENE EXPRESSION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CORTEX; MESANGIUM CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; TRANSFORMING GROWTH FACTOR BETA1 GENE; UPREGULATION;

EID: 80052248898     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.43     Document Type: Article

References (54)

1. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993; 22: 736-744. (Pubitemid 23330946)
2. Brosius FC, Khoury CC, Buller CL et al. Abnormalities in signaling pathways in diabetic nephropathy. Expert Rev Endocrinol Metab 2010; 5: 51-64.
3. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146.
4. Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 2007; 104: 3432-3437. (Pubitemid 46364176)
5. Yamamoto T, Nakamura T, Noble NA et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818. (Pubitemid 23069947)
6. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97: 7667-7669. (Pubitemid 30460701)
7. Park IS, Kiyomoto H, Abboud SL et al. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997; 46: 473-480. (Pubitemid 27090278)
8. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020. (Pubitemid 30460765)
9. Zhu Y, Casado M, Vaulont S et al. Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes 2005; 54: 1976-1984. (Pubitemid 40911259)
10. Wang S, Skorczewski J, Feng X et al. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factorbeta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem 2004; 279: 34311-34322. (Pubitemid 39318055)
11. Weigert C, Brodbeck K, Sawadogo M et al. Upstream stimulatory factor (USF) proteins induce human TGF-beta1 gene activation via the glucoseresponse element-1013/-1002 in mesangial cells: up-regulation of USF activity by the hexosamine biosynthetic pathway. J Biol Chem 2004; 279: 15908-15915. (Pubitemid 38509278)
12. Kato M, Wang L, Putta S et al. Posttranscriptional upregulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem 2010; 285: 34004-34015.
13. Sekido R, Murai K, Funahashi J et al. The delta-crystallin enhancer-binding protein delta EF1 is a repressor of E2-box-mediated gene activation. Mol Cell Biol 1994; 14: 5692-5700.
14. Verschueren K, Remacle JE, Collart C et al. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 50-CACCT sequences in candidate target genes. J Biol Chem 1999; 274: 20489-20498.
15. Eger A, Aigner K, Sonderegger S et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005; 24: 2375-2385. (Pubitemid 40546696)
16. Ponticos M, Partridge T, Black CM et al. Regulation of collagen type I in vascular smooth muscle cells by competition between Nkx2.5 and deltaEF1/ZEB1. Mol Cell Biol 2004; 24: 6151-6161. (Pubitemid 38891118)
17. Murray D, Precht P, Balakir R et al. The transcription factor deltaEF1 is inversely expressed with type II collagen mRNA and can repress Col2a1 promoter activity in transfected chondrocytes. J Biol Chem 2000; 275: 3610-3618. (Pubitemid 30083071)
18. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11: 252-263.
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
20. Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689.
21. Elmen J, Lindow M, Schutz S et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-899. (Pubitemid 351550859)
22. Kato M, Putta S, Wang M et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009; 11: 881-889.
23. Kato M, Arce L, Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol 2009; 4: 1255-1266.
24. Wang Q, Wang Y, Minto AW et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008; 22: 4126-4135.
25. Wang XX, Jiang T, Shen Y et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 2010; 59: 2916-2927.
26. Chung AC, Huang XR, Meng X et al. miR-192 mediates TGF-{beta}/Smad3- driven renal fibrosis. J Am Soc Nephrol 2010; 21: 1317-1325.
27. Krupa A, Jenkins R, Luo DD et al. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 438-447.
28. Wei Q, Bhatt K, He HZ et al. Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 2010; 21: 756-761.
29. Gregory PA, Bert AG, Paterson EL et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601. (Pubitemid 351627379)
30. Park SM, Gaur AB, Lengyel E et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907. (Pubitemid 351482843)
31. Burk U, Schubert J, Wellner U et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589. (Pubitemid 351772923)
32. Korpal M, Lee ES, Hu G et al. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
33. Hurteau GJ, Carlson JA, Spivack SD et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007; 67: 7972-7976. (Pubitemid 47395127)
34. Christoffersen NR, Silahtaroglu A, Orom UA et al. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA 2007; 13: 1172-1178. (Pubitemid 47080461)
35. Wang B, Herman-Edelstein M, Koh P et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010; 59: 1794-1802.
36. Bracken CP, Gregory PA, Kolesnikoff N et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846-7854.
37. Kato M, Natarajan R. microRNA cascade in diabetic kidney disease: big impact initiated by a small RNA. Cell Cycle 2009; 8: 3613-3614.
38. Geiser AG, Kim SJ, Roberts AB et al. Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol 1991; 11: 84-92. (Pubitemid 21895184)
39. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20. (Pubitemid 40094598)
40. Braun CJ, Zhang X, Savelyeva I et al. p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68: 10094-10104.
41. Yang S, Du J, Wang Z et al. Dual mechanism of deltaEF1 expression regulated by bone morphogenetic protein-6 in breast cancer. Int J Biochem Cell Biol 2009; 41: 853-861.
42. Zeisberg M, Bonner G, Maeshima Y et al. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 2001; 159: 1313-1321. (Pubitemid 32947961)
43. Shintani Y, Fukumoto Y, Chaika N et al. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J Cell Biol 2008; 180: 1277-1289. (Pubitemid 351468480)
44. Wang G, Kwan BC, Lai FM et al. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens 2010; 23: 78-84.
45. Wang G, Kwan BC, Lai FM et al. Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest 2010; 90: 98-103.
46. Dai Y, Sui W, Lan H et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 2009; 29: 749-754.
47. Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? Cell 2000; 102: 407-410.
48. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1: 233-240. (Pubitemid 33741898)
49. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799. (Pubitemid 39070849)
50. Adorno M, Cordenonsi M, Montagner M et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137: 87-98.
51. Zhou L, Fu P, Huang XR et al. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 2010; 21: 31-41.
52. Hyun S, Lee JH, Jin H et al. Conserved microRNA miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K. Cell 2009; 139: 1096-1108.
53. Kato M, Yuan H, Xu ZG et al. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol 2006; 17: 3325-3335. (Pubitemid 44865275)
54. Mahimainathan L, Das F, Venkatesan B et al. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 2006; 55: 2115-2125. (Pubitemid 44509987)